ATE499940T1 - CARBONATE AND CARBAMAT PRODRUGS OF THIAZOLO Δ4,5-DÜ-PYRIMIDINES - Google Patents

CARBONATE AND CARBAMAT PRODRUGS OF THIAZOLO Δ4,5-DÜ-PYRIMIDINES

Info

Publication number
ATE499940T1
ATE499940T1 AT07799643T AT07799643T ATE499940T1 AT E499940 T1 ATE499940 T1 AT E499940T1 AT 07799643 T AT07799643 T AT 07799643T AT 07799643 T AT07799643 T AT 07799643T AT E499940 T1 ATE499940 T1 AT E499940T1
Authority
AT
Austria
Prior art keywords
prodrugs
thiazolo
carbonate
carbamat
pyrimidines
Prior art date
Application number
AT07799643T
Other languages
German (de)
Inventor
Gregory Haley
Joseph Lennox
Alan Xiang
Stephen Webber
Original Assignee
Anadys Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anadys Pharmaceuticals Inc filed Critical Anadys Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE499940T1 publication Critical patent/ATE499940T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)

Abstract

The invention is directed to carbonate and carbamate prodrugs of thiazolo[4,5-d]pyrimidine compounds, whose metabolized parent compound has immunomodulatory activity. The invention also relates to the therapeutic use of such prodrugs and pharmaceutical compositions thereof in treating disease states associated with abnormal cell growth, such as cancer.
AT07799643T 2006-07-18 2007-07-17 CARBONATE AND CARBAMAT PRODRUGS OF THIAZOLO Δ4,5-DÜ-PYRIMIDINES ATE499940T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83145506P 2006-07-18 2006-07-18
PCT/US2007/073681 WO2008011406A2 (en) 2006-07-18 2007-07-17 Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines

Publications (1)

Publication Number Publication Date
ATE499940T1 true ATE499940T1 (en) 2011-03-15

Family

ID=38957547

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07799643T ATE499940T1 (en) 2006-07-18 2007-07-17 CARBONATE AND CARBAMAT PRODRUGS OF THIAZOLO Δ4,5-DÜ-PYRIMIDINES

Country Status (7)

Country Link
US (1) US7528115B2 (en)
EP (1) EP2040712B1 (en)
JP (1) JP5225991B2 (en)
AT (1) ATE499940T1 (en)
BR (1) BRPI0714831A2 (en)
DE (1) DE602007012881D1 (en)
WO (1) WO2008011406A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7321033B2 (en) * 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
AU2006318260B2 (en) 2005-11-21 2012-05-17 Anadys Pharmaceuticals, Inc. Process for the preparation of 5-amino-3H- thiazolo [4 , 5 -d] pyrimidin- 2 -one
KR101461604B1 (en) * 2006-06-22 2014-11-18 애나디스 파마슈티칼스, 인코포레이티드 Prodrugs of 5-amino-3-(3'-deoxy-β-D-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione
US20110166092A1 (en) * 2007-08-20 2011-07-07 Anadys Pharmaceuticals, Inc. Dosing methods for treating disease
WO2016055553A1 (en) 2014-10-11 2016-04-14 F. Hoffmann-La Roche Ag Compounds for use in the treatment of infectious diseases
UA124184C2 (en) 2014-12-08 2021-08-04 Ф. Хоффманн-Ля Рош Аг 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
EP3845227A1 (en) 2015-03-16 2021-07-07 F. Hoffmann-La Roche AG Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
CN107743491B (en) 2015-05-08 2020-08-21 豪夫迈·罗氏有限公司 Novel oxathiolanecarboxylic acids and derivatives thereof for the treatment and prevention of viral infections
EP3294746B1 (en) 2015-05-12 2021-10-06 F. Hoffmann-La Roche AG Substituted aminothiazolopyrimidinedione derivatives for the treatment and prophylaxis of virus infection
JP6839104B2 (en) 2015-06-30 2021-03-03 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ A novel substitution aminothiazolopyrimidinedione for the treatment and prevention of viral infections
CN110234656B (en) 2016-09-09 2023-02-28 卡利泰拉生物科技公司 Exonucleotidase inhibitors and methods of use thereof
EP3546457B1 (en) 2016-11-28 2021-07-14 Jiangsu Hengrui Medicine Co., Ltd. Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
BR112019012327A2 (en) 2016-12-22 2019-11-19 Calithera Biosciences Inc ectonucleotidase inhibitors and methods of use thereof
EP3568400A1 (en) 2017-01-06 2019-11-20 H. Hoffnabb-La Roche Ag PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED 5-AMINO-6H-THIAZOLO[4,5-d]PYRIMIDINE-2-7-DIONE COMPOUNDS
WO2018210298A1 (en) 2017-05-18 2018-11-22 江苏恒瑞医药股份有限公司 Heteroaryl-pyrazole derivative, and preparation method therefor and medical application thereof
US10675296B2 (en) 2017-07-11 2020-06-09 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
EP3808745A4 (en) 2018-05-25 2022-03-09 Jiangsu Hengrui Medicine Co., Ltd. Crystal form of hydrochloride of pyrazoloheteroaryl derivative and preparation method
JP2021529172A (en) 2018-06-21 2021-10-28 キャリセラ バイオサイエンシーズ， インコーポレイテッド Ectonucleotidase inhibitor and how to use it
AU2020298440B2 (en) * 2019-06-18 2023-10-05 Taiho Pharmaceutical Co., Ltd. Novel phosphate ester compound having pyrrolopyrimidine skeleton or pharmaceutically acceptable salt thereof
AU2021214911A1 (en) 2020-01-27 2022-07-21 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
KR20220164784A (en) 2020-04-06 2022-12-13 길리애드 사이언시즈, 인코포레이티드 Inhalation Formulations of 1′-Cyano Substituted Carbanucleoside Analogues
JP2023528810A (en) 2020-05-29 2023-07-06 ギリアード サイエンシーズ， インコーポレイテッド remdesivir treatment method
CN115996928A (en) 2020-06-24 2023-04-21 吉利德科学公司 1' -cyanonucleoside analogs and uses thereof
KR20230057411A (en) 2020-08-27 2023-04-28 길리애드 사이언시즈, 인코포레이티드 Compounds and methods for treating viral infections
EP4320128A1 (en) 2022-03-02 2024-02-14 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US733566A (en) 1903-03-16 1903-07-14 August Sundh Electric controller.
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
ZA791659B (en) 1978-04-17 1980-04-30 Ici Ltd Process and apparatus for spraying liquid
US4539205A (en) 1982-11-09 1985-09-03 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US4643992A (en) 1982-11-09 1987-02-17 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US5166141A (en) 1983-11-01 1992-11-24 Scripps Clinic And Research Foundation Immunostimulating 7-deaza-7-oxa- and 7-deaza-7-oxo-analogs of 8-substituted-guanine-9-(1'-beta-D-aldoglycosidyl) derivatives and methods of treating test animals
US4746651A (en) 1983-11-01 1988-05-24 Scripps Clinic And Research Foundation Antimicrobial chemotherapeutic potentiation using substituted nucleoside derivatives
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
GB8712745D0 (en) 1987-05-30 1987-07-01 Wellcome Found Antiviral compounds
US5041426A (en) 1987-12-21 1991-08-20 Brigham Young University Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides
US4880784A (en) * 1987-12-21 1989-11-14 Brigham Young University Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives
DE3815221C2 (en) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Use of a retinol and / or retinoic acid ester-containing pharmaceutical preparation for inhalation for acting on the mucous membranes of the tracheo-bronchial tract, including the lung alveoli
US5041542A (en) 1988-06-03 1991-08-20 Nucleic Acid Research Institute Substituted pyrimido[5,4-d]pyrimidine nucleosides
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (en) 1989-03-22 1991-07-25 Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
GB9015914D0 (en) 1990-07-19 1990-09-05 Wellcome Found Heterocyclic compounds
US5248672A (en) 1990-11-01 1993-09-28 The Regents Of The University Of Michigan Polysubstituted benzimidazole nucleosides as antiviral agents
GB9105899D0 (en) 1991-03-20 1991-05-08 Wellcome Found Therapeutic nucleosides
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
AU5165793A (en) 1992-10-01 1994-04-26 Mcneilab, Inc. Derivatives of 7,8-disubstituted guanosines
GB9225098D0 (en) 1992-12-01 1993-01-20 Coffee Ronald A Charged droplet spray mixer
GB9226717D0 (en) 1992-12-22 1993-02-17 Coffee Ronald A Induction-operated electro-hydrodynamic spray device with means of modifying droplet trajectories
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5994321A (en) 1993-12-20 1999-11-30 Aronex Pharmaceuticals, Inc. Antiviral guanine analogs
US5446045A (en) 1993-12-20 1995-08-29 Revankar; Ganapathi R. Antiviral guanine analogs
GB9406255D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
GB9406171D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
GB9410658D0 (en) 1994-05-27 1994-07-13 Electrosols Ltd Dispensing device
IT1270594B (en) 1994-07-07 1997-05-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
JP3142577B2 (en) 1995-03-14 2001-03-07 シーメンス アクチエンゲゼルシヤフト Removable precision metering unit
NZ304009A (en) 1995-03-14 1999-02-25 Siemens Ag Ultrasonic atomizer device with a removable precision dosating unit
WO1998001448A1 (en) 1996-07-03 1998-01-15 Japan Energy Corporation Novel purine derivatives
KR100386140B1 (en) 1996-10-16 2003-06-02 아이씨엔 파마슈티컬스, 인코포레이티드 Purine l-nucleosides, analogs and uses thereof
US6509320B1 (en) 1996-10-16 2003-01-21 Icn Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses thereof
HUP9904665A3 (en) 1996-10-25 2000-11-28 Minnesota Mining And Mfg Co Sa Immune response modifier compounds for treatment of th2 mediated and related diseases
NZ504021A (en) 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
US6329381B1 (en) 1997-11-28 2001-12-11 Sumitomo Pharmaceuticals Company, Limited Heterocyclic compounds
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
ATE404561T1 (en) 2001-04-17 2008-08-15 Dainippon Sumitomo Pharma Co NEW ADENINE DERIVATIVES
KR100718371B1 (en) 2001-11-27 2007-05-14 애나디스 파마슈티칼스, 인코포레이티드 3-?-D-RIVOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
KR20050006221A (en) 2002-05-06 2005-01-15 제네랩스 테크놀로지스, 인코포레이티드 Nucleoside derivatives for treating hepatitis c virus infection
WO2005016235A2 (en) 2003-04-14 2005-02-24 The Regents Of The University Of California Combined use of impdh inhibitors with toll-like receptor agonists
ES2342069T4 (en) * 2003-09-05 2011-01-26 Anadys Pharmaceuticals, Inc. TLR7 LINKS FOR THE TREATMENT OF HEPATITIS C.
AR052995A1 (en) 2004-12-17 2007-04-18 Anadys Pharmaceuticals Inc COMPOUNDS OF 3H-OXAZOLO AND 3H-TIAZOLO [4, 5 - D] PIRIMIDIN-2-ONA3, 5-DISABLED AND 3, 5, 7-TRISUSTITUTED WITH IMMUNOMODULATING ACTIVITY, ITS PROFARMACOS, PHARMACEUTICAL COMPOSITIONS THAT THEY CONNECT TO THEM TREATMENT OF VIRAL ORIGIN DISEASES
KR101461604B1 (en) 2006-06-22 2014-11-18 애나디스 파마슈티칼스, 인코포레이티드 Prodrugs of 5-amino-3-(3'-deoxy-β-D-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione

Also Published As

Publication number Publication date
EP2040712A2 (en) 2009-04-01
US7528115B2 (en) 2009-05-05
EP2040712A4 (en) 2010-04-14
EP2040712B1 (en) 2011-03-02
JP5225991B2 (en) 2013-07-03
DE602007012881D1 (en) 2011-04-14
JP2009543884A (en) 2009-12-10
US20080020989A1 (en) 2008-01-24
WO2008011406A2 (en) 2008-01-24
BRPI0714831A2 (en) 2013-04-02
WO2008011406A3 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
ATE499940T1 (en) CARBONATE AND CARBAMAT PRODRUGS OF THIAZOLO Δ4,5-DÜ-PYRIMIDINES
EA200701504A1 (en) INDOLS SUITABLE FOR THE TREATMENT OF INFLAMMATION
EA200701808A1 (en) Derivatives of tetrahydroindolone and tetrahydroindazole
EA200800172A1 (en) 2,4-DIAMINOPYRIMIDINES AS AURORA INHIBITORS
NO20081315L (en) Benzokinazoline derivatives and their use in the treatment of bone disorders
TW200637820A (en) Indoles useful in the treatment of inflammation
EA201070597A1 (en) ANTIBACTERIAL ANALOGUES OF AMINOGLICOSIDE
EA200800664A1 (en) PYRROPOLYMIDINE DERIVATIVES AS SYK INHIBITORS
TW200716628A (en) Novel compounds
MX2007013624A (en) Protein kinase inhibitors.
EA201100794A1 (en) SUBSTITUTED PYRIMIDINES INTENDED FOR THE TREATMENT OF DISEASES, SUCH AS CANCER
EA200800100A1 (en) COMPOUNDS OF AZAINDAZOL AND METHODS OF APPLICATION
MX2009000333A (en) Pyrrolopyrimidines for pharmaceutical compositions.
EA200970296A1 (en) CONTAINING DIARYL ETHER OF UREA COMPOUNDS
TW200630374A (en) Thiazolyldihydroindazoles
EA200971104A1 (en) Derivatives of benzimidazole
TW200700393A (en) Novel cis-2,4,5-triaryl-imidazolines
EA200970575A1 (en) COMPOUNDS ON THE BASIS OF 4-PHENYL-6- (2,2,2-TRIFTOR-1-PHENYLETOXI) Pyrimidine and methods for their use
SG10201809895YA (en) Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
EA200801287A1 (en) Pyrimidine derivatives for the treatment of anomalous cell growth
ATE478863T1 (en) HETEROTETRACYCLIC COMPOUNDS AS TPOMIMETICA
TW200509892A (en) Novel aminobenzophenone compounds
WO2007150002A3 (en) PRODRUGS OF 5-AMINO-3-(3'-DEOXY-β-D-RIBOFURANOSYL)-THIAZOLO[4,5-d] PYRIMIDIN-2,7-DIONE
EA200800302A1 (en) APPLICATION OF DERIVATIVES AND ANALOGUES OF THIAZOLE IN TREATMENT OF CANCER
EA200801107A1 (en) PYRAZOLS, SUITABLE FOR THE TREATMENT OF INFLAMMATION

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties